FIELD: biotechnology.
SUBSTANCE: following is described: a method of in vitro diagnosis of a tumor caused by or otherwise associated with cells expressing V-domain immunoglobulin suppressor of T-cell activation (VISTA) in a subject and the use of an anti-VISTA therapeutic agent for the preparation of a medicinal product for the treatment of cancer caused or otherwise associated with VISTA-expressing cells in a patient, wherein the said treatment includes the preliminary stage of diagnosing the said cancer in the said patient using the above in vitro tumor diagnostic method. The method includes the steps of contacting a biological sample from a specified subject with a reagent capable of specifically binding to P-selectin glycoprotein ligand 1 (PSGL-1) nucleic acid or PSGL-1 protein; and quantifying the binding of the said reagent to the said biological sample, thereby determining the level of expression of PSGL-1 in the said sample.
EFFECT: invention expands the range of diagnostic tools for tumors caused by or otherwise associated with cells expressing VISTA.
11 cl, 13 dwg, 12 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER DISEASES | 2019 |
|
RU2799547C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| CD37-BINDING MOLECULES AND THEIR IMMUNOCONJUGATES | 2011 |
|
RU2742743C2 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
| TETRAVALENT ANTIBODIES TO PSGL-1 AND THEIR APPLICATIONS | 2017 |
|
RU2766000C2 |
